For research use only. Not for therapeutic Use.
SB 202190 (Cat No.:I001887) is a selective inhibitor of p38 mitogen-activated protein kinase (MAPK), a signaling molecule involved in various cellular processes, including inflammation and stress response. By inhibiting p38 MAPK, SB 202190 suppresses the activation of downstream signaling pathways and the production of pro-inflammatory cytokines. This compound has been widely used in research studies to investigate the role of p38 MAPK in various diseases, such as inflammation, cancer, and neurodegenerative disorders. SB 202190 has shown potential therapeutic benefits in preclinical models, and its use has contributed to a better understanding of p38 MAPK signaling and its implications in disease pathogenesis.
| Catalog Number | I001887 |
| CAS Number | 152121-30-7 |
| Synonyms | 4-[4-(4-fluorophenyl)-5-pyridin-4-yl-1,3-dihydroimidazol-2-ylidene]cyclohexa-2,5-dien-1-one |
| Molecular Formula | C₂₀H₁₄FN₃O |
| Purity | ≥95% |
| Target | p38 |
| Solubility | DMSO: ≥ 40 mg/mL |
| Storage | 3 years -20C powder |
| IC50 | 50 nM (p38α); 100 nM (p38β) |
| IUPAC Name | 4-[4-(4-fluorophenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]phenol |
| InChI | InChI=1S/C20H14FN3O/c21-16-5-1-13(2-6-16)18-19(14-9-11-22-12-10-14)24-20(23-18)15-3-7-17(25)8-4-15/h1-12,25H,(H,23,24) |
| InChIKey | QHKYPYXTTXKZST-UHFFFAOYSA-N |
| SMILES | C1=CC(=CC=C1C2=NC(=C(N2)C3=CC=NC=C3)C4=CC=C(C=C4)F)O |
| Reference | </br>1:A Single Amino Acid Substitution Makes WNK4 Susceptible to SB 203580 and SB 202190. Glover M, Sweeny C, Davis B, O/’Shaughnessy KM.Open Med Chem J. 2010 Sep 3;4:57-61. doi: 10.2174/1874104501004010057. PMID: 21249167 Free PMC Article</br>2:Non-specific in vivo inhibition of CK1 by the pyridinyl imidazole p38 inhibitors SB 203580 and SB 202190. Shanware NP, Williams LM, Bowler MJ, Tibbetts RS.BMB Rep. 2009 Mar 31;42(3):142-7. PMID: 19336000 Free PMC Article |
